Weekly Paclitaxel Combining with Gemcitabine is an Effective and Safe Treatment for Advanced Breast Cancer Patients

Rau, Kun‐Ming; Li, Shan-Hsuan; Chen, Shyr-Ming Sheen; Tang, Yen Zhi; Huang, Cheng-Hua; Wu, Shih-Chung; Chen, Yen‐Yang

doi:10.1093/jjco/hyq232

Cited by 9 publications

(4 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, we obtained similar results to those achieved with standard regimens administered to metastatic breast cancer patients but avoiding toxicity. Accordingly, the use of gemcitabine and carboplatin plus iniparib yielded a 56% OCB rate [25], while the administration of capecitabine and vinorelbine in HER2-negative patients reached a OCB rate of 70% [26] and the combination of paclitaxel with gemcitabine resulted in a 80% OCB rate [27].…”

Section: Discussionmentioning

confidence: 99%

Safety and Therapeutic Effect of Metronomic Chemotherapy with Cyclophosphamide and Celecoxib in Advanced Breast Cancer Patients

et al. 2013

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Safety and Therapeutic Effect of Metronomic Chemotherapy with Cyclophosphamide and Celecoxib in Advanced Breast Cancer Patients

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Several small-size studies have confirmed the tolerability and efficacy of wGT. 7 – 9 Although similar efficacy was observed between wGT and triweekly GT in phase III trials, wGT is widely used in clinical practice due to its convenience in terms of dose adjustment and patient management. 10 – 12 …”

Section: Introductionmentioning

confidence: 78%

“…[10][11][12] Research on optimization of the dosage regimen of wGT is ongoing. Two regimens of wGT have been widely accepted and used in the real world after years of practice: the 28-day regimen (GT on days 1, 8, and 15, every 28 days) 7,[12][13][14][15] and the 21-day regimen (GT on days 1 and 8, every 21 days). [9][10][11][16][17][18] To the best of our knowledge, no study has investigated the difference between the two wGT regimens in terms of efficacy, safety, or patient preference.…”

Section: Introductionmentioning

confidence: 99%

Comparison of two regimens of weekly paclitaxel plus gemcitabine in patients with metastatic breast cancer: propensity score–matched analysis of real-world data

Gong

Xie

Zhao

et al. 2022

Therapeutic Advances in Drug Safety

View full text Add to dashboard Cite

Purpose: Weekly gemcitabine + paclitaxel (wGT) administration is widely applied in real-world clinical practice. The 28-day and 21-day regimens of wGT are the most widely accepted regimens. We evaluated the efficacy and safety of wGT administration in patients with metastatic breast cancer (MBC) and compared the two regimens. Methods: Patients with human epidermal growth factor receptor 2 (HER-2)-negative MBC who received wGT between October 2013 and October 2016 were identified using an electronic database. The outcome variables included progression-free survival (PFS), overall survival (OS), objective response rate (ORR), and safety profile. Propensity score matching was performed to minimize potential confounders. Results: A total of 140 patients were included. The median PFS and OS was 7.8 [95% confidence interval (CI) = 7.0–8.7] months and 22.5 (95% CI = 18.8–26.1) months, respectively. The toxicity of wGT was manageable. Among the patients, 90 (64.3%) received the 21-day regimen and 50 (35.7%) received the 28-day regimen. A higher number of younger patients and patients receiving later-line therapy received the 28-day regimen. There was no significant difference between the two groups in PFS after propensity score matching, though subgroup analysis showed that patients with early relapse benefited more from the 28-day regimen. The ORR was numerically higher in 28-day regimen (37.8% versus 28.0%, p = 0.310). However, the 21-day regimen was better tolerated than the 28-day regimen. Conclusion: wGT administration showed efficacy and safety in patients with MBC. The efficacy was comparable between the two regimens after adjustment for confounding factors while the 21-day regimen was better tolerated. Plain Language Summary 21-day regimen of wGT was well tolerated in patients with metastatic breast cancer Weekly gemcitabine + paclitaxel (wGT) administration is widely applied in real-world clinical practice. The 28-day and 21-day regimens of wGT are the most widely accepted regimens. We evaluated the efficacy and safety of wGT administration in patients with metastatic breast cancer (MBC) and compared the two regimens. Patients with human epidermal growth factor receptor 2 (HER-2)-negative MBC who received wGT between October 2013 and October 2016 were identified using an electronic database. The outcome variables included progression-free survival (PFS), overall survival (OS), objective response rate (ORR), and safety profile. Propensity score matching was performed to minimize potential confounders. We found that the efficacy was comparable between the two regimens after adjustment for confounding factors while the 21-day regimen was better tolerated.

show abstract

“…Regarding the treatment and maintenance polychemotherapy used in breast cancer, the use of paclitaxel combined with gemcitabine has shown better results than monotherapy with paclitaxel [8], one of the options recommended as first-line treatment [7]. Currently, there is no consensus on the optimal duration of the doublet protocol for maintenance therapy.…”

Section: Discussionmentioning

confidence: 99%

Complete and Sustained Response with a Doublet Chemotherapy Protocol in an 81-Year-Old Patient with Metastatic Breast Cancer

Puty¹,

Brito²,

Dias³

et al. 2016

Case Rep Oncol

View full text Add to dashboard Cite

Metastatic breast cancer (MBC) entails an overall 5-year survival of approximately 25%. The choice of therapy is influenced by expression of the HER2 gene and hormone receptors, by a disease-free interval, and by age. The use of paclitaxel combined with gemcitabine (doublet protocol) has shown efficacy as first-line treatment for MBC in either initial or maintenance therapy when compared to monotherapy with paclitaxel. There is evidence showing that the doublet protocol is a good alternative to maintenance therapy in women under 50 years old. Nevertheless, there is a lack of information concerning individuals above that age. We report the case of an 81-year-old patient presenting with recurrence of MBC, with lung and skin metastases both positive for hormone receptor and negative for HER2. We implemented a therapy based on the combination of gemcitabine and paclitaxel for 12 cycles, when complete response was achieved. Currently, 16 months after this achievement, the patient is receiving maintenance treatment under the doublet protocol, presenting acceptable parameters of toxicity since the beginning of treatment, which shows satisfactory tolerability and management of chemotherapy in an elderly patient. We suggest that the maintenance treatment protocol with a doublet might be an alternative with a satisfactory response in patients with MBC.

show abstract

Weekly Paclitaxel Combining with Gemcitabine is an Effective and Safe Treatment for Advanced Breast Cancer Patients

Cited by 9 publications

References 21 publications

Safety and Therapeutic Effect of Metronomic Chemotherapy with Cyclophosphamide and Celecoxib in Advanced Breast Cancer Patients

Safety and Therapeutic Effect of Metronomic Chemotherapy with Cyclophosphamide and Celecoxib in Advanced Breast Cancer Patients

Comparison of two regimens of weekly paclitaxel plus gemcitabine in patients with metastatic breast cancer: propensity score–matched analysis of real-world data

Complete and Sustained Response with a Doublet Chemotherapy Protocol in an 81-Year-Old Patient with Metastatic Breast Cancer

Contact Info

Product

Resources

About